Clinical Trial Update: A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 trial in advanced esophageal squamous cell carcinoma is evaluating investigational agents with or without pembrolizumab in patients who have p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Esophageal Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: RECRUITING